Tuesday, May 21, 2024
HomeClinical Trials and ResearchIs Lumacaftor-Ivacaftor for cystic fibrosis safe and effective?

Is Lumacaftor-Ivacaftor for cystic fibrosis safe and effective?

Cystic fibrosis (CF) is a genetic disorder, caused by mutations in the cystic fibrosis transmembrane conductance regulator protein. Clinically, CF contributes to the dysfunction of multiple organs and negatively affects the airway, which makes breathing difficult. Patients with CF are also at a higher risk of infections and malnutrition. In 2015, the Food and Drug Administration and the European Medicines Agency approved the combination therapy of lumacaftor-ivacaftor for CF. Several clinical trials demonstrated that the lumacaftor-ivacaftor combination successfully improved lung function and body-mass index. Despite its success, however, some recent research suggests that lumacaftor-ivacaftor may be associated with a higher risk of discontinuation than previously appreciated.

A recent study published in the American Journal of Respiratory and Critical Care Medicine investigated the safety and effectiveness of lumacaftor-ivacaftor therapy. The authors recruited 845 CF patients, including 292 adolescents and 553 adults, from 47 centers across France. Over the course of the study, 154 patients (18.2%) had to discontinue their treatment due to adverse respiratory and non-respiratory events. This proportion is relatively high when compared to previous studies which have reported that less than 5% of patients discontinue their lumacaftor-ivacaftor treatment. Importantly, however, the individuals that continued taking the drugs were found to have an improvement in lung function and body weight. In contrast, patients that discontinued treatment were found to be at a higher risk of lung dysfunction, malnutrition, and adverse respiratory events.

The study reported that while lumacaftor-ivacaftor was associated with improved lung function and nutritional status, the proportion of patients that discontinued treatment due to adverse events was surprisingly high. The authors reasoned that the high discontinuation rate may be explained by the fact that they included a higher proportion of patients with a more severe and unstable CF disease. Additional studies with a large patient cohort are necessary to further validate the safety and effectiveness of lumacaftor-ivacaftor for CF. It is also important to note that lumacaftor-ivacaftor therapy was approved for patients with a specific CF mutation.

 

Written by Haisam Shah

 

Reference: Burgel, P. R., Munck, A., Durieu, I., Chiron, R., Mely, L., Prevotat, A., … & Marguet, C. (2019). Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis. American journal of respiratory and critical care medicine, (ja).

Image by mcmurryjulie from Pixabay

 

Haisam Shah BSc
Haisam Shah BSc
Haisam is a first-year Masters student in the Department of Physiology at the University of Toronto. His research involves understanding the role of cardiac fibroblasts in the progressive development of cardiac fibrosis following a myocardial infarction. He graduated from McGill University with a Bachelors of Science – Honors in Pharmacology, where he had the opportunity of investigating potential combination therapies for Glioblastoma Multiforme.
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest News and Articles

SUBSCRIBE TO OUR NEWSLETTERS

Stay Connected
10,288FansLike
820FollowersFollow
249FollowersFollow
2,787FollowersFollow

Article of the month

Recognizing HIE: A Call for Advocacy

Have you heard of HIE? It’s the second leading cause of infant mortality and lifelong disability worldwide. 2-3 per 1,000 live births in high-income...

Joke Of The Day – May 21

Recently in the news,  it was announced that The New England Medical Journal reports:  9 out of 10 doctors agree that 1 out of...

ADVERTISE WITH US

error: Content is read-only and copy-protected.